The University of Nevada, Reno School of Medicine

Linking Pathways to Progress: Optimizing Treatment Selection in Atopic Dermatitis

MD, PhD, MSCI

Utilize the latest clinical data to differentiate available biologic IL-13 therapies and guide therapy selection 

Evaluate the safety and efficacy of emerging IL-13 therapies to support timely integration into clinical practice 

Discuss evidence-based approaches to personalizing treatment plans to optimize the management of moderate-to-severe AD with IL-13 biologics 

large_279_covergraphic.jpg

medium_279_covergraphic.jpg

small_279_covergraphic.jpg

thumbnail_279_covergraphic.jpg

279_covergraphic.jpg

Atopic dermatitis (AD) is a chronic, relapsing inflammatory dermatosis characterized by epidermal barrier dysfunction, type 2–skewed immune activation, and intense pruritus with eczematous lesions. Disease expression varies by age and severity, with recurrent flares and a well-established association with atopic comorbidities including asthma, allergic rhinitis, and food allergy.

This hub gathers the evidence, expert perspective, and practical insight shaping how atopic dermatitis is understood and treated today, connecting emerging therapies with the everyday decisions that define long-term care.

WCM26: Linking Pathways to Progress: Optimizing Treatment Selection in Atopic Dermatitis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures